Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms
12.9.2022 15:00:00 EEST | Business Wire | Press release
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has raised $90 million in a Series C financing, bringing its total funding raised to date to $330 million. The current round was co-led by Drive Capital and Aisling Capital with an additional undisclosed strategic investor.
“We continue our ambitious mission to enable access to life changing gene therapies by fulfilling a key goal of bringing them from concept to reality,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics. “To deliver on that mission, we’ve made great strides in our facility development, technology advancement, and hiring expansion. These new funds will help support this next measured phase of our growth focused on delivering new services to our clients so that we can support them from idea to impact. Each advancement we make goes towards serving our clients and their patient communities, and we are grateful to our investors for their confidence in our mission.”
The Company will use the funding to expand client offerings, including proprietary technologies, manufacturing systems, cell lines, and additional services to bolster its end-to-end manufacturing platform. Through the Company’s 200,000 square foot cGMP facility dedicated to AAV viral vector manufacturing, Forge will expand the number of offerings available to clients to help scale gene therapy programs from research to clinical and commercial manufacturing in its 20 cGMP suites utilizing its operational 50L, 500L, 1,000L and 5,000L bioreactors.
“Forge has grown tremendously over the last two years, hiring experienced talent and scaling the facility, technology, and client offerings according to their unique hybrid business model,” said Molly Bonakdarpour, General Partner at Drive Capital. “We believe that Forge is becoming an established leader in gene therapy manufacturing, consistent with Drive Capital’s focus to build and support market-defining companies.”
“We have confidence in the caliber of leadership at Forge, their technical expertise at all levels, and the meticulous attention to detail in every facet of the business,” said Andrew Schiff, M.D., Managing Partner at Aisling Capital. “The gene therapy industry has been constrained by technical, operational, and capacity constraints, and Forge is poised to tackle each of those areas to alleviate the manufacturing bottleneck as they set out to do.”
Recent Milestones Reached
Technology:
- Hired notable talent for key technical roles with gene therapy-specific expertise: Agnieszka Gornicka, Ph.D., Director, GMP Manufacturing; Ganesh Krishnamoorthy, Associate Director, Process Development
- Scaled the Company’s proprietary HEK 293 suspension platform process from 50L to 1000L
- Integrated new systems into its platform process such as single-use chromatography and automated fill-finish
Facility Expansion:
- Increased overall manufacturing footprint to over 200,000 square feet; buildout includes 20 cGMP suites utilizing 50L, 500L, 1,000L, and 5,000L bioreactors, with additional cGMP suites planned
Manufacturing Expertise:
- Formed an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development with a distinct and strategic emphasis on manufacturing advancements
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005350/en/
Contact information
Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com
Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations
Investors@forgebiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom